enGene Therapeutics (ENGN) Net Income (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Net Income of -$30.2 million for Q2 2026, down 17.09% year-over-year from -$36.5 million in Q2 2025, and down 1.6% quarter-over-quarter from -$29.8 million in Q1 2026.
enGene Therapeutics (ENGN) Net Income (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Net Income for 4 consecutive years, with -$30.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Income fell 17.09% year-over-year to -$30.2 million; the TTM figure through Apr 2026 stood at -$23.1 million (up 71.05% YoY), while the FY2025 annual figure was -$13.6 million, up 75.38% from the prior year.
- Net Income eased to -$30.2 million in Q2 2026 per ENGN's latest filing, from -$29.8 million in the prior quarter.
- Across five years, Net Income topped out at $65.8 million in Q4 2025 and bottomed at -$82.5 million in Q4 2023.
- Historically, Net Income has averaged -$16.3 million across 4 years, with a median of -$15.1 million in 2024.
- Annual changes were most pronounced in 2024 — Net Income sank 199.75% — and 2025, when it jumped 530.4%.
- enGene Therapeutics' Net Income stood at -$82.5 million in 2023, then surged by 81.46% to -$15.3 million in 2024, then surged by 530.4% to $65.8 million in 2025, then tumbled by 145.9% to -$30.2 million in 2026.
- Business Quant data shows ENGN's Net Income at -$30.2 million in Q2 2026, -$29.8 million in Q1 2026, and $65.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | -30.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -30.23 Mn |
| Jan 31, 2026 | -29.75 Mn |
| Oct 31, 2025 | 65.85 Mn |
| Jul 31, 2025 | -28.99 Mn |
| Apr 30, 2025 | -25.82 Mn |
| Jan 31, 2025 | -24.62 Mn |
| Oct 31, 2024 | -15.30 Mn |
| Jul 31, 2024 | -14.15 Mn |
| Apr 30, 2024 | -14.98 Mn |
| Jan 31, 2024 | -10.71 Mn |
| Oct 31, 2023 | -82.50 Mn |
| Jul 31, 2023 | -4.72 Mn |
| Apr 30, 2023 | -5.28 Mn |
| Jan 31, 2023 | -7.42 Mn |